N&PD Moderators: Skorpio | thegreenhand
I'm fairly certain that what you are referring to is the combination of selegiline and phenethylamine, which although doesn't 'convert' to methamp, for all intents and purposes acts in the same fashion as methamp.
MAO A has noradrenaline as a substrate, meaning metabolises it. Phenethylamine releases a large amount of noradrenaline into the synapse (moreso than dopamine). So if you inhibit MAO A, you can get a hypertensive crisis from when the levels of noradrenaline skyrocket, activating dem a1, a2, b1, b2, b3 receptors and pimpin dem hoes.
MAOI's are interesting regardless. I'm thinking of investing in one and trying the above combo. Also as a vegan I don't have to worry as much about the whole food interaction thing.
Let's say that it requires a little more commitment, knowledge and discipline than other medications and a MAOI card in the neck in case medical eventualities.^ No it's not for safety reasons (it's an irreversible/non-competetive MAOI)
For selegiline you have to consume at least 30mg to get any positive mood lift.
I dont recommend this to beginners though.
I think I would prefer "trany" to this selegiline stuff, although ive still not tried it yet.
I disagree with the idea of patients being unable to function without it being indicative of any abuse potential; by your definition, insulin has abuse potential. I wouldn't say it's indicative at all of dependence (in the sense relating to addiction); unfortunately many diseases simply aren't curable, and the best that modern medicine can offer people suffering from those is medication that reduces the symptoms to a more tolerable level. IMHO, that does not make these people addicts.I have run into patients who cannot live with out it with any quality of life and other (all other classes) have failed. They don't abuse it but that indicates to me the potential is there.
An astute observation. Aside from reboxetine - which is a dubious example because it doesn't fall into any of the categories you listed and clinical trials were pretty unfavourable - it's notable that most DRI/NDRI drugs were among the earlier drugs developed, hence the ones whose patents expired earliest (similar is true of MAOIs, barbiturates - like methaqualone which you mention - and a lot of tricyclics, which have all similarly fallen out of favour).To wit the US was roundly against any DRI, SDRI, NDRI with any potency, reboxetine, mianserin until regranted a label as 6-aza (mirtazapine), doxulepin, amoxapine, really weird lists. Methysergide is schedule 1 now, like methqualone.
It's the patents I think.